Country: Canada
Language: English
Source: Health Canada
CISATRACURIUM (CISATRACURIUM BESYLATE)
ABBVIE CORPORATION
M03AC11
CISATRACURIUM
2MG
LIQUID
CISATRACURIUM (CISATRACURIUM BESYLATE) 2MG
INTRAVENOUS
10 ML(VIAL)
Prescription
NEUROMUSCULAR BLOCKING AGENTS
Active ingredient group (AIG) number: 0133260001; AHFS:
CANCELLED POST MARKET
2016-06-07
_NIMBEX_ _®_ _ Product Monograph _ _Page 1 of 34 _ PRODUCT MONOGRAPH PR NIMBEX ® cisatracurium besylate injection solution for injection (2 mg/mL) Non-depolarizing Skeletal Neuromuscular Blocking Agent THIS DRUG SHOULD BE ADMINISTERED ONLY BY ADEQUATELY TRAINED PROFESSIONALS FAMILIAR WITH ITS ACTIONS, CHARACTERISTICS, AND HAZARDS. NOTE: NIMBEX ® is a trademark of the Glaxo group of companies, AbbVie Corporation licensed use. _ _ Date of Preparation: November 1, 2012 AbbVie Corporation 8401 Trans-Canada Highway St-Laurent, Qc H4S 1Z1 Submission Control No: 158348 _NIMBEX_ _®_ _ Product Monograph _ _Page 2 of 34 _ TABLE OF CONTENTS PART I: HEALTH PROFESSIONAL INFORMATION ..........................................................3 SUMMARY PRODUCT INFORMATION ........................................................................3 INDICATIONS AND CLINICAL USE ..............................................................................3 CONTRAINDICATIONS ...................................................................................................4 WARNINGS AND PRECAUTIONS ..................................................................................4 ADVERSE REACTIONS ....................................................................................................9 DRUG INTERACTIONS ..................................................................................................11 DOSAGE AND ADMINISTRATION ..............................................................................12 OVERDOSAGE ................................................................................................................18 ACTION AND CLINICAL PHARMACOLOGY ............................................................18 STORAGE AND STABILITY ..........................................................................................26 SPECIAL HANDLING INSTRUCTIONS .......................................................................26 DOSAGE FORMS, COMPOSITION AND PACKAGING ........................................ Read the complete document